Plinabulin – Lead Compound

Lead Compound

BeyondSpring’s lead oncology asset, Plinabulin, is a novel small molecule with immune-enhancing effects and anti-cancer activity that induces dendritic cell maturation and their production of cytokines that are important in maintaining neutrophil survival. Plinabulin targets and alters the tumor microenvironment, activating GEF-H1, and has shown the potential to address currently unmet medical needs, including preventing neutropenia induced by chemotherapy as well as improving outcomes as a second-line and third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Plinabulin has been granted composition and usage patents in 34 countries, including the U.S, E.U., Japan and China. Plinabulin’s patent estate holds the potential to protect the asset to 2038.

Plinabulin has been administered in more than 140 patients through now completed Phase 1 and 2 trials. It has proven to be well-tolerated and has shown encouraging anti-tumor activity. In the first half of 2017, BeyondSpring initiated two Phase 2/3 registration studies for Plinabulin for the prevention of chemotherapy-induced neutropenia. The Company is also conducting a large, single Phase 3 study of Plinabulin for second-line and third-line NSCLC, which was initiated in 2016 following feedback from the U.S. FDA, and is taking place in the U.S., China, and western countries.

For more information about Neutropenia and Plinabulin’s clinical program for the prevention of chemotherapy-induced Neutropenia, please click here (password is blayney) for an interview with Dr. Douglas Blayney, Professor of Medicine at Stanford School of Medicine and Primary Investigator on BeyondSpring’s ongoing Phase 3 Plinabulin studies in Neutropenia.

For more information about Non Small Cell Lung Cancer (NSCLC) and Plinabulin’s clinical program for this indication, please click here (password is Mita) for an interview with Dr. Alain Mita, of Cedars-Sinai Medical Center, Los Angeles, who presented BeyondSpring’s Phase 2 NSCLC data at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in February 2017.